MOR103, a human monoclonal antibody to granulocyte–macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial - Behrens, Frank; Tak, Paul P.; Østergaard, Mikkel; Stoilov, Rumen; Wiland, Piotr; Huizinga, Thomas W.; Berenfus, Vadym Y.; Vladeva, Stoyanka; Rech, Juergen; Rubbert-Roth, Andrea; Korkosz, Mariusz; Rekalov, Dmitriy; et al. (Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), 2015)
Aus: Annals of the Rheumatic Diseases 74.6 (2015): S. 1058-1064. <http://ard.bmj.com/content/74/6/1058>